Zymeworks’ new CEO Kenneth Galbraith has vastly remade the nearly 20-year-old biotech in the few short months he’s run the show. But his efforts to turn things around have apparently ruffled some feathers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,